Induction therapy after cardiac transplantation: A comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection

ATG and daclizumab are equally effective in preventing acute rejections requiring treatment (ISHLT Grade ≥2). Due to the significantly greater frequency of Grade 1 rejections, daclizumab was found to be associated with an increased number of additional biopsies for monitoring rejection status. This implies additional costs to the transplant program, and the long-term implications of the increased number of low-grade rejection episodes remains to be determined.